Search our Innovation Portfolio

PUFFClicker3 is an Internet-of-Things-connected universal Smart Inhaler Dose Tracker for metered dose and dry powder inhalers. PUFFClicker3 connects to the Asthma+me platform for children and young people (CYP) at high risk of further asthma attacks who are already being seen in Outpatient clinics by a Consultant Paediatrician and to Active+me REMOTE for adults with respiratory health conditions.
In SBRI Healthcare Competition 23, Phase 1, Children and Young People will be asked how this PUFFClicker3 could be used to help them better manage their asthma and how this could be deployed in the Community near to where they live.

Exhale-Dx represents an innovative diagnostic breath test platform adept at predicting asthma attacks and effectively monitoring asthma control. By harnessing artificial intelligence Exhale-Dx meticulously analyzes breath samples for biomarkers, offering a non-invasive and early-detection solution for various respiratory conditions. Our ongoing project focuses on adapting Exhale-Dx for pediatric use, aiming to expand its global reach. This device holds the potential to identify asthma exacerbations before they escalate. Particularly in underserved communities, where access to healthcare may be limited, early detection can mitigate the need for emergency room visits and hospitalisations, thus reducing health disparities through timely intervention.

TidalSense has patented an innovative fast-response CO2 sensor within a connected, handheld and battery-operated handset (N-Tidal Handset). TidalSense has also developed, and is ready to bring to market N-Tidal Diagnose, software with embedded AI algorithms that can sensitively detect changes in lung physiology consistent with COPD. Class 2a EU MDR regulatory approval for N-Tidal Diagnose is anticipated in calendar Q1/Q2 2025.

This project will develop prototype AI-derived asthma diagnostic software to be combined with N-Tidal hardware for children and determine how it could be used in clinical practice.